Pitch Introduction
The Nemocare Shark Tank India pitch stands as a powerful example of how deep-tech healthcare solutions can address critical survival challenges in developing nations. Founders Pratyusha Pareddy and Manoj Sanker entered the tank with a clear mission: to reduce infant mortality using their flagship product, Nemocare Raksha. This wearable, clinical-grade device is designed specifically for newborns, particularly those born premature or with low birth weight, providing a safety net that is often missing in rural or overburdened hospital settings.
During the pitch, the founders highlighted a heartbreaking reality: India loses approximately 4 Lakh babies annually due to conditions like apnea and hypothermia, which are often preventable with timely intervention. By bringing their IoT-enabled solution to the Sharks, the founders sought not just capital, but a strategic partner to help scale their life-saving technology across India and international markets. The presentation immediately caught the attention of Aman Gupta and Peyush Bansal, though the journey to a deal was filled with intense scrutiny over their business model and valuation.
Business Overview
Nemocare is a Hyderabad and Bangalore-based health-tech startup that focuses on neonatal and maternal care. Established in 2016, the company spent several years in research and development, supported by prestigious grants from organizations like the Bill and Melinda Gates Foundation and the Department of Biotechnology (DBT). Their core innovation, Nemocare Raksha, is a smart wearable that fits onto a baby’s foot like a tiny sock, monitoring vital signs continuously without the need for cumbersome wires or expensive stationary monitors.
The problem Nemocare solves is twofold. First, in high-traffic NICUs (Neonatal Intensive Care Units), a single nurse often monitors dozens of babies simultaneously. Nemocare’s centralized dashboard allows for real-time alerts if a baby’s oxygen levels or heart rate drop, ensuring immediate medical attention. Second, in rural areas where sophisticated incubators are scarce, this portable device provides high-end monitoring at a fraction of the cost, bridging the gap between urban hospitals and village healthcare centers.
Product Details
The Nemocare Raksha device is a clinical-grade, portable wearable that tracks four essential vital parameters: heart rate, respiration rate, body temperature, and oxygen saturation (SpO2). It utilizes an AI platform to not only monitor current health but also predict potential future distress conditions, giving doctors a critical window for intervention. The device connects wirelessly to a central station via IoT technology, allowing doctors to monitor babies remotely from any corner of the hospital or even from different locations.
Market Position
Nemocare occupies a unique niche in the Medical/Health industry by offering a clinical-grade accuracy (validated at 99% for SpO2) in a form factor that is significantly more affordable and portable than traditional multipara monitors. Unlike consumer-grade baby monitors that are designed for home use, Nemocare Raksha is built for the rigors of hospital environments and has already secured a US Patent. Their competitive advantage lies in their unique revenue models, including subscription-based and CSR-driven deployments, making it accessible to even small 20-bedded nursing homes in Tier 2 and Tier 3 cities.
| Business Detail | Information |
|---|---|
| Company Name | Nemocare |
| Founders | Pratyusha Pareddy and Manoj Sanker |
| Product Type | Wearable Neonatal Monitor |
| Price Range | ₹60,000 (Device) or Subscription Model |
| Primary Channel | B2B (Hospitals/NICU) and CSR |
| Headquarters | Hyderabad, Telangana / Bangalore, Karnataka |
About Founder’s
The founders of Nemocare, Pratyusha Pareddy and Manoj Sanker, bring a combination of engineering prowess and design thinking to the table. Manoj, an engineer from PES University, Bangalore, further honed his skills in product design at the prestigious NID Ahmedabad. Pratyusha, based in Hyderabad, comes from a family of doctors, which deeply influenced her passion for solving healthcare gaps. According to The Indian Express, both founders were fellows at the Center for Healthcare Entrepreneurship (CfHE) at IIT-H, where they spent a year in field research observing the struggles in newborn care.
- Manoj Sanker: Expert in product design and engineering with a focus on medical devices.
- Pratyusha Pareddy: Healthcare entrepreneur with deep roots in medical clinical needs.
- Grant Recipients: Secured funding from the Bill & Melinda Gates Foundation ($100k) and DBT.
- Research-Driven: Spent a full year in immersive hospital research before incorporating in 2016.
Shark’s and Founder’s QnA
What are the chances of survival for a baby born in a small town with low birth weight?
In a big city, the chances are quite high, but in a small town or village where the majority of the Indian population lives, the survival chance for a 1.2 kg baby is less than 50%. Every year, India loses 4 lakh babies who could have been saved with timely intervention.
How does the Nemocare Raksha device work?
It is a clinical-grade portable device that goes on the baby’s foot. It tracks vitals like heart rate, respiration, and oxygen saturation in real-time. The data is relayed wirelessly to a nursing station dashboard, so one nurse can monitor 40 babies simultaneously with the help of technology.
What is your revenue model for small nursing homes that cannot afford big machines?
We have a subscription model where we don’t charge for the device. We charge ₹600 per baby until discharge. They use a patch that costs us ₹50 to make, and the hospital marks it up through their pharmacy, making it a revenue share for them as well.
Why hasn’t your revenue grown significantly in the last three years?
We have been refining the product and focusing on large maternal health programs and CSR models. We are currently at a ₹90 Lakhs yearly run rate, and we are also focusing on the US FDA approval process to open global pathways and gain more domestic confidence.
Peyush, why are you concerned about our valuation and focus?
Peyush felt that by chasing US FDA approval and American cash, we might be ignoring the 10 lakh children in India. He argued that the valuation of ₹40 Crores was a burden that might force us to focus only on high-paying markets rather than the impact in India.
What is your current burn and profitability?
We actually broke even last year. Our burn was minimal, around ₹15 Lakhs for the full fiscal year 2023, which was largely matched by the grants we received. We are very efficient with capital as we haven’t diluted any equity until this round.
Key Stats & Financials
At the time of the Nemocare Shark Tank India pitch, the company demonstrated strong unit economics despite being in a niche, high-barrier medical market. They had successfully avoided equity dilution for over six years, relying on grants and organic growth to reach their current scale.
Revenue and Profitability
- Yearly Revenue: ₹90 Lakhs
- Gross Margin: 66%
- Original Valuation Requested: ₹40 Crores
- Investment Request: ₹1 Crore for 2.5% equity
- Burn Rate: ₹15 Lakhs (Fiscal Year 2023)
Financial Breakdown
| Metric | Amount / Value |
|---|---|
| Manufacturing Cost (Device) | ₹1 Lakh |
| Selling Price (CSR/Bulk) | ₹3 Lakhs |
| Consumable Patch Cost | ₹50 |
| Consumable Selling Price | ₹200 to ₹500 |
| Subscription Fee | ₹600 per baby |
| Grants Received | ₹6 Crores (approx.) |
Business Potential and TAM
The total addressable market for neonatal monitoring is massive, driven by a global surge in healthcare infrastructure spending and a growing focus on reducing infant mortality rates (IMR). The global neonatal infant care market is projected to reach several billion dollars, with India representing one of the largest segments due to its high birth rate. With over 80 Lakh babies born with low birth weight in India every year, the domestic potential for a low-cost, high-accuracy monitor is immense.
Market Size Analysis
The global neonatal monitoring market is estimated to be worth over $2 Billion, growing at a CAGR of roughly 6-8%. In India, the market is shifting from expensive imported machinery to homegrown “Make in India” solutions. Nemocare’s ability to provide ICU-grade monitoring in a portable format positions them to capture market share from both the traditional medical device giants and the emerging consumer-focused home monitoring startups.
Growth Opportunities
- US FDA Approval: Securing FDA clearance will allow Nemocare to enter the lucrative North American market and increase domestic trust.
- Direct-to-Consumer: Expanding from hospital-only use to a home-monitoring model for concerned parents of premature babies.
- Government Partnerships: Leveraging the National Health Mission to integrate Raksha into district hospitals and primary health centers.
- Data Monetization: Using their vast AI-driven vital parameter database to provide predictive health insights to insurance and research firms.
Nemocare: Ideal Target Audience & Demographics
| Demographic | Details |
|---|---|
| Primary Customer | NICU & Maternity Hospital Management |
| Secondary Customer | CSR Foundations and Govt Health Depts |
| Target End User | Newborns (0-28 days) with medical distress | B2B LinkedIn, Medical Conferences, Direct Sales |
| Geography | Tier 2 and Tier 3 Indian Cities, Global Export |
| Buying Behavior | Volume based bulk orders or pay-per-use |
Marketing and Distribution Strategy
Nemocare’s marketing strategy is heavily focused on clinical validation and B2B partnerships rather than mass-market advertising. By securing patents and participating in clinical trials, they build the necessary credibility required in the healthcare industry. Their presence in major South Indian hospitals serves as a proof of concept for national expansion.
Customer Acquisition
The company acquires customers primarily through medical equipment distributors and direct outreach to hospital networks. They also leverage CSR (Corporate Social Responsibility) funding, where large corporations like Google or HCL fund the deployment of Nemocare devices in underserved regions. Their Customer Acquisition Cost (CAC) for hospitals is offset by the long-term recurring revenue generated from the consumable sensor patches.
Distribution Channels
- Direct Hospital Sales: Targeting large corporate hospital chains for upfront sales.
- Leasing/Subscription: Providing devices to smaller nursing homes with a pay-per-baby model.
- CSR Channels: Partnering with NGOs and foundations for large-scale rural deployments.
- International Distributors: Currently exploring partnerships in Africa and Southeast Asia for exports.
Social Media and Content Strategy
On social media, Nemocare focuses on educational content about neonatal health and showcasing the real-world impact of their technology. Their LinkedIn presence is crucial for connecting with healthcare professionals and potential investors. According to NorthEast Now, their visibility on platforms like Shark Tank has significantly amplified their message of innovation in the maternal and child health space.
Nemocare Shark Tank Deal Outcome
The negotiation for Nemocare was one of the most debated of Season 3. While Namita Thapar and Vineeta Singh offered a combined deal at a ₹10 Crores valuation, the founders felt this was too low given their US patent and grant history. Peyush Bansal offered ₹1 Crore (₹10 Lakhs equity and ₹90 Lakhs debt) but his criticism of their “US-focus” created friction. Ultimately, Aman Gupta offered a more balanced deal that the founders accepted.
| Shark | Offer Detail |
|---|---|
| Aman Gupta | ₹20 Lakhs for 0.67% equity + ₹80 Lakhs debt @ 10% interest for 2 years |
| Peyush Bansal | ₹10 Lakhs for 1% equity + ₹90 Lakhs debt @ 0% interest (Matched Aman later) |
| Namita Thapar & Vineeta Singh | ₹50 Lakhs for 5% equity + ₹50 Lakhs debt @ 10% interest |
| Anupam Mittal | Out – Felt the business model was too early for his commercial style |
| Final Decision | Accepted Aman Gupta’s Offer |
Nemocare Post-Show Update
Following their appearance, the founders expressed mixed emotions regarding the feedback from the Sharks. In an interview with The Indian Express, Manoj Sanker noted his disappointment with Peyush Bansal’s criticism, suggesting a potential bias. Despite the on-screen friction, the brand received immense recognition, helping them advance their US FDA approval process and expand their deployments in South India. Verified post-show revenue figures for Nemocare are not yet available, but the brand continues to focus on its goal of saving 10 Lakh babies in the next three years.
Business Analysis & Lessons
The Nemocare pitch highlights the delicate balance between impact-driven startups and venture capital expectations. While the Sharks praised the technology, the debate over valuation showed that investors often struggle to price companies that have grown through non-dilutive grants. The pivot from a pure hardware sale to a subscription-based model was a critical strategic move that demonstrated the founders’ understanding of the Indian hospital ecosystem’s cash flow constraints.
A key lesson for medical tech entrepreneurs here is the importance of clinical validation and Intellectual Property (IP). Nemocare’s US patent and high accuracy levels were their biggest bargaining chips, allowing them to reject low-ball offers and hold out for a deal that respected their years of R&D. However, Peyush’s critique also serves as a reminder to always keep the primary mission (saving lives in India) at the forefront of the narrative, even when pursuing global expansion.
Key Takeaways
- Non-Dilutive Capital: Grants are excellent for R&D but can complicate equity valuation discussions later on.
- Pricing Innovation: Changing from a ₹1 Lakh device sale to a ₹600 subscription per baby makes expensive tech accessible.
- Global vs Local: Pursuing high-end certifications like US FDA is essential for global credibility, even for a domestic-first product.
- Clinical Validation: In healthcare, data accuracy (99% SpO2 in this case) is the most critical metric for investor and doctor trust.
Pitch Conclusion
Nemocare’s journey on Shark Tank India Season 3 was a testament to the power of persistent innovation. By securing a ₹1 Crore deal with Aman Gupta, the company gained more than just capital; it gained a partner known for scaling brands across India. As they continue their path toward saving 10 Lakh babies, Nemocare serves as a beacon for other “deep-tech” startups looking to make a real-world impact. If you enjoyed this breakdown, check out MeduLance, Neuphony, and Matri.
[faq_accordian]